Results 91 to 100 of about 122 (100)

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine, 2008
Stephen Macmahon, John Chalmers, Bruce Neal   +2 more
exaly  

Type 2 diabetes as an inflammatory disease

Nature Reviews Immunology, 2011
Marc Y Donath, Steven E Shoelson, Donath Marc Y   +2 more
exaly  

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine, 2015
Bernard Zinman, Christoph Wanner, John M Lachin   +2 more
exaly  

Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance

New England Journal of Medicine, 2001
Jaana Lindstr̈Om, Johan G Eriksson, T T Valle   +2 more
exaly  

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine, 2008
Hertzel C Gerstein, Robert P Byington, J Thomas Bigger   +2 more
exaly  

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine, 2016
Steven P Marso, Agostino Consoli, Esteban Jódar   +2 more
exaly  

Leptin revisited: its mechanism of action and potential for treating diabetes

Nature Reviews Drug Discovery, 2012
Roberto Coppari, Christian Bjørbæk, Coppari Roberto   +2 more
exaly  

ANDROGEN DEPRIVATION RAISES RISK OF DIABETES, HEART DISEASE

Ca-A Cancer Journal for Clinicians, 2007
exaly  

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

New England Journal of Medicine, 2019
Vlado Perkovic, Meg J Jardine, Bruce Neal   +2 more
exaly  

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
Itamar Raz, Marc P Bonaca, Ofri Mosenzon   +2 more
exaly